Catalent bringing clinical supply services to Japanese facility

By Dan Stanton contact

- Last updated on GMT

Image: iStock/Flaz81
Image: iStock/Flaz81

Related tags: Japan

Catalent will expand its cGMP facility in Japan to bring secondary packaging and clinical supply services to the region.

The 200,000 sq. ft. cGMP facility in Kakegawa, Japan has been operating for over 40 years, providing a range of manufacturing services.

Now Catalent intends to offer local and regional customers clinical supply services direct from the site.

“We previously performed any necessary packaging work at a Catalent facility outside of the region and then imported the finished goods into an in-country depot for distribution to our customers' clinical sites within Japan,”​ Amy Lombardi, Group Product Manager, Catalent Clinical Supply Services, told Outsourcing-Pharma.com.

“Having a facility in Japan that offers secondary packaging, along with clinical storage and distribution services, offers our customers greater flexibility and improves supply chain efficiency.”  

The site will form part of the New Jersey, US-headquartered firm’s Asian-Pacific clinical supply network, which includes a full service clinical packaging facility in Shanghai, cold-chain and secondary packaging and clinical storage facility in Singapore.

“This investment boosts a critical part of our business capabilities in Asia-Pacific by adding the ability to support global and local pharma companies' clinical trial needs from Japan,”​ Lombardi continued.

“It will provide local capabilities, with dedicated local resources and expertise, to better serve multinational customers' Japanese studies and Japanese pharma's global studies, in addition to domestic only studies.”

Lombardi did not divulge financial details or whether the expansion would create any new jobs.

Catalent in Japan

The announcement is the latest in a line of recent investments in Japan by the contract development and manufacturing organisation (CDMO).

In 2014​, Catalent announced it was opening an oral formulation development lab and expanding its OptiGel micro softgel manufacturing capacity at the Kakegawa site.

The firm has also been forging a number of biologics R&D partnerships in the region, including an agreement with the Center for iPS (induced pluripotent stem) Cell Research and Application (CiRA)​ at Kyoto University and teamed up with Mitsubishi Gas Chemical Company​ to make cell lines for the region.

Related news

Show more

Related products

show more

QPS: Global Custom-Built Research Services

QPS: Global Custom-Built Research Services

QPS | 16-Dec-2019 | Product Brochure

Performing complex studies in special populations with remarkable agility. Clinical research just got better with QPS’ Custom-Built Research Services....

Validating The Simoa Technology

Validating The Simoa Technology

Frontage Laboratories | 01-Oct-2019 | Technical / White Paper

Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...

Related suppliers

Follow us

Products

View more

Webinars